Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1985 May; 78(5): 367–372.
PMCID: PMC1289716

Captopril for refractory hypertension in patients with impaired renal function.


The use of captopril in 19 patients with renal parenchymal disease and refractory hypertension was studied for a mean period of 12 months. There was a significant reduction in the systolic and diastolic blood pressures, with a reduction in the mean arterial pressure of 29 mmHg. The mean maintenance dose of captopril was 142 mg daily in three divided doses. All but one of the patients required a diuretic for satisfactory blood pressure control and 3 patients were also given a beta-blocker. In all patients a simplification of the previous therapeutic regimen was achieved. A significant rise in serum creatinine was noted in 2 patients, one of whom had to be withdrawn from the study. Despite the presence of renal functional impairment, proteinuria did not occur de novo nor did established proteinuria increase. Leukopenia was noted in any of the patients in this group.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (705K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Andrén L, Karlberg B, Ohman P, Svensson A, Asplund J, Hansson L. Captopril and atenolol combined with hydrochlorothiazide in essential hypertension. Br J Clin Pharmacol. 1982;14 (Suppl 2):107S–111S. [PMC free article] [PubMed]
  • Atkinson AB, Brown JJ, Fraser R, Leckie B, Lever AF, Morton JJ, Robertson JI. Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I and II and aldosterone, and in body composition. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):139s–143s. [PubMed]
  • Atkinson AB, Brown JJ, Lever AF, Robertson JI. Combined treatment of severe intractable hypertension with captopril and diuretic. Lancet. 1980 Jul 19;2(8186):105–108. [PubMed]
  • Atkinson AB, Brown JJ, Lever AF, McAreavey D, Robertson JI, Behan PO, Melville ID, Weir AI. Neurological dysfunction in two patients receiving captopril and cimetidine. Lancet. 1980 Jul 5;2(8184):36–37. [PubMed]
  • Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979 Jan;90(1):19–23. [PubMed]
  • Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis. 1978 Nov-Dec;21(3):195–206. [PubMed]
  • Case DB, Atlas SA, Marion RM, Laragh JH. Long-term efficacy of captopril in renovascular and essential hypertension. Am J Cardiol. 1982 Apr 21;49(6):1440–1446. [PubMed]
  • Case DB, Atlas SA, Mouradian JA, Fishman RA, Sherman RL, Laragh JH. Proteinuria during long-term captopril therapy. JAMA. 1980 Jul 25;244(4):346–349. [PubMed]
  • Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med. 1977 Mar 24;296(12):641–646. [PubMed]
  • Collste P, Haglund K, Lundgren G, Magnusson G, Ostman J. Reversible renal failure during treatment with captopril. Br Med J. 1979 Sep 8;2(6190):612–613. [PMC free article] [PubMed]
  • Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983 Feb 17;308(7):377–381. [PubMed]
  • Farrow PR, Wilkinson R. Reversible renal failure during treatment with captopril. Br Med J. 1979 Jun 23;1(6179):1680–1680. [PMC free article] [PubMed]
  • Ferguson RK, Vlasses PH, Koplin JR, Shirinian A, Burke JF, Jr, Alexander JC. Captopril in severe treatment-resistant hypertension. Am Heart J. 1980 May;99(5):579–585. [PubMed]
  • Forslund T, Borgmastars H, Fyrquist F. Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure. Lancet. 1981 Jan 17;1(8212):166–166. [PubMed]
  • Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4;298(18):991–995. [PubMed]
  • Gavras I, Graff LG, Rose BD, McKenna JM, Brunner HR, Gavras H. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981 Jan;94(1):58–59. [PubMed]
  • Grossman A, Eckland D, Price P, Edwards CR. Captopril: reversible renal failure with severe hyperkalaemia. Lancet. 1980 Mar 29;1(8170):712–712. [PubMed]
  • Hamilton DV, Evans DB, Maidment G, Pryor JS. Captopril for refractory hypertension in patients with chronic renal failure and renal transplantation. J R Soc Med. 1981 May;74(5):357–362. [PMC free article] [PubMed]
  • Havelka J, Boerlin HJ, Studer A, Greminger P, Tenschert W, Luescher T, Siegenthaler W, Vetter W, Walger P, Vetter H. Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 1982;14 (Suppl 2):71S–76S. [PMC free article] [PubMed]
  • Havelka J, Vetter H, Studer A, Greminger P, Lüscher T, Wollnik S, Siegenthaler W, Vetter W. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol. 1982 Apr 21;49(6):1467–1474. [PubMed]
  • Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980 Dec;20(6):409–452. [PubMed]
  • Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. N Engl J Med. 1979 Jul 5;301(1):9–12. [PubMed]
  • Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. 1981 Aug;20(2):240–245. [PubMed]
  • Hoorntje SJ, Kallenberg CG, Weening JJ, Donker AJ, The TH, Hoedemaeker PJ. Immune-complex glomerulopathy in patients treated with captopril. Lancet. 1980 Jun 7;1(8180):1212–1215. [PubMed]
  • Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983 Feb 17;308(7):373–376. [PubMed]
  • Karlberg BE, Asplund J, Wettre S, Ohman KP, Nilsson OR. Long-term experience of captopril in the treatment of primary (essential) hypertension. Br J Clin Pharmacol. 1982;14 (Suppl 2):133S–137S. [PMC free article] [PubMed]
  • Kincaid-Smith P, Whitworth JA, Walter NM, Dowling JP. Immune complex glomerulopathy and captopril. Lancet. 1980 Jul 5;2(8184):37–37. [PubMed]
  • McGiff JC, Quilley J. Prostaglandins, kinins and the regulation of blood pressure. Clin Exp Hypertens. 1980;2(3-4):729–740. [PubMed]
  • MacGregor GA, Markandu ND, Roulston JE, Jones JC. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme. Br Med J. 1979 Nov 3;2(6198):1106–1109. [PMC free article] [PubMed]
  • Mancia G, Parati G, Pomidossi G, Grassi G, Bertinieri G, Buccino N, Ferrari A, Gregorini L, Rupoli L, Zanchetti A. Modification of arterial baroreflexes by captopril in essential hypertension. Am J Cardiol. 1982 Apr 21;49(6):1415–1419. [PubMed]
  • Marks ES, Bing RF, Thurston H, Swales JD. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat. Clin Sci (Lond) 1980 Jan;58(1):1–6. [PubMed]
  • Moore TJ, Crantz FR, Hollenberg NK, Koletsky RJ, Leboff MS, Swartz SL, Levine L, Podolsky S, Dluhy RG, Williams GH. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension. 1981 Mar-Apr;3(2):168–173. [PubMed]
  • Prins EJ, Hoorntje SJ, Weening JJ, Donker AJ. Nephrotic syndrome in patient on captopril. Lancet. 1979 Aug 11;2(8137):306–307. [PubMed]
  • Raine AE, Ledingham JG. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am J Cardiol. 1982 Apr 21;49(6):1475–1479. [PubMed]
  • Santucci A, Aguglia F, De Mattia G, Ficara C, Balsano F. Long-term captopril treatment in moderate to severe hypertension. Br J Clin Pharmacol. 1982;14 (Suppl 2):77S–79S. [PMC free article] [PubMed]
  • Seedat YK. Nephrotic syndrome from captopril. S Afr Med J. 1980 Mar 15;57(11):390–390. [PubMed]
  • Staessen J, Fagard R, Lijnen P, Amery A. Captopril and agranulocytosis. Lancet. 1980 Apr 26;1(8174):926–927. [PubMed]
  • Tarazi RC, Bravo EL, Fouad FM, Omvik P, Cody RJ., Jr Hemodynamic and volume changes associated with captopril. Hypertension. 1980 Jul-Aug;2(4):576–585. [PubMed]
  • Woodhouse K, Farrow PR, Wilkinson R. Reversible renal failure during treatment with captopril. Br Med J. 1979 Nov 3;2(6198):1146–1147. [PMC free article] [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press